Regulatory Open Forum

 View Only
  • 1.  Assessing changes for a grandfathered product

    Posted 11 days ago

    Hello, 

    If there is an old product which does not have all the Modules and only Module 1 is present in the dossier, which is possible for products from 60's or 70's. 

    How do we assess a change then ? Changes made in manufacturing now would require assessment to look at Module 3, 4, 5 sections, and if they are not present, then how do we assess the regulatory impact of the change ? 

    Looking forward to hearing from the industry experts.

    Regards, 

    Raushan Blake



    ------------------------------
    Raushan Blake
    Regulatory Affairs Specialist
    Viatris
    Inverin, Galway
    Ireland
    ------------------------------


  • 2.  RE: Assessing changes for a grandfathered product

    Posted 10 days ago

    For the EU, the MDR does not allow any grandfathering.  Your product needs to be always State of the Art



    ------------------------------
    Armin Beck
    CEO
    SunTrixConsulting LLC
    El Dorado Hills, CA
    1-925-212-7683
    armin.beck@suntrixmedical.com
    ------------------------------



  • 3.  RE: Assessing changes for a grandfathered product

    Posted 9 days ago

    Hello Armin, 


    Thank you for the response. For devices, I have understood that there is no such provision under the MDR, how about drugs though? 

    Regards, 



    ------------------------------
    Raushan Blake
    Regulatory Affairs Specialist
    Viatris
    Inverin, Galway
    Ireland
    ------------------------------



  • 4.  RE: Assessing changes for a grandfathered product

    Posted 9 days ago

    I'm curious, too. The guidance doesn't seem very prescriptive.

    https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management_en.pdf

    https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf

    I'd guess it may not be practical to generate a complete Module 3 retroactively for a low-margin product, but over the decades some process control work has probably been done. I wonder how much data may be available to support a risk-based decision.



    ------------------------------
    Anne LeBlanc
    United States
    ------------------------------



  • 5.  RE: Assessing changes for a grandfathered product

    Posted 8 days ago

    Sorry, I do not know drugs.



    ------------------------------
    Armin Beck
    CEO
    SunTrixConsulting LLC
    El Dorado Hills, CA
    1-925-212-7683
    armin.beck@suntrixmedical.com
    ------------------------------